Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This editorial emphasizes the critical need for laser protection supervisors in the aesthetic sector due to a rise in laser-related claims attributed to inadequate training and safety protocol adherence, highlighting that better understanding and supervision can help mitigate risks.

This guideline by the British Association of Dermatologists reviews managing alopecia areata and provides 56 recommendations but reports no new clinical results.

In this updated guideline, the British Association of Dermatologists' expert group provided 49 management recommendations for alopecia areata and highlighted future research priorities, aiming to improve care for individuals affected by this condition.

This systematic review found that licensed hair gloss products in the UK provide significant cosmetic benefits like improved shine and smoothness, but 18% contain harmful additives, highlighting the need for stricter regulations and patient education on product safety.

This article discusses approaches to diagnosing and treating androgenetic alopecia but reports no new clinical results.

JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.

This article discusses the JCCP's new Premises Standards for aesthetic practitioners, focusing on how these guidelines help ensure patient safety, and reports no new research findings.

This study found that most UK women prescribed cyproterone acetate/ethinylestradiol before and after 2013 had conditions aligning with approved indications and prior acne treatment.

This source details the process necessary to substantiate "clinically proven" claims for products, emphasizing the importance of rigorous clinical trials, regulatory compliance, and emerging technologies in ensuring safety, efficacy, and credibility across diverse populations and settings.

This article discusses the need for changes in governance and regulation within the aesthetics industry, focusing on creating standards and competency frameworks to ensure safe practices. Results are not reported in this summary.

This article discusses the physiology of hair growth, how to identify excessive hair growth in women, and when to refer them for further medical assessment, but reports no new clinical results.

This document discusses the British Association of Dermatologists' current perspective on isotretinoin, focusing on its known side effects, prescribing requirements, teratogenic risks, and the contentious link to mood changes, reporting no new research findings.

This review found that platelet-rich plasma was effective in increasing hair follicle cell activity and capillary density in alopecia treatment, with enhanced outcomes when combined with microneedling or minoxidil.

This review highlights the potential of regenerative medicine therapies, such as biologics and emerging technologies, to significantly impact aesthetic and reconstructive procedures in plastic surgery and dermatology.

This study found that using electronic healthcare record data can provide valuable early insights into the clinical context of about half of the new safety signals evaluated within a regulatory environment.

This review discusses female androgenetic alopecia, highlighting its diagnostic challenges and management strategies, but it reports no new results.

This study found that finasteride caused adverse effects on liver, kidney, and heart tissues in female mice, raising concerns about its potential use in females for treating androgenetic alopecia.

Testosterone replacement can help menopausal women with various symptoms, but should be used carefully and is not yet officially licensed in the UK for women.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

In this study analyzing FDA data, researchers found that tralokinumab was associated with higher reports of conjunctivitis and keratitis compared to dupilumab, while dupilumab had more frequent injection site reactions, highlighting potential risks for clinical monitoring in atopic dermatitis treatments.

This article discusses acne vulgaris as a prevalent skin disease affecting the pilosebaceous unit and provides no new clinical findings.

Dental professionals should ensure safety in facial aesthetics by being properly trained and registered.

This review examines the direct-to-consumer genetic testing market, highlighting the available tests, regulatory issues, and calls for increased oversight, and reports no new results.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

This review of interventions for alopecia areata found no significant treatment benefits for hair growth compared to placebo, indicating a need for larger, well-conducted studies.

This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.

This case report highlights a 53-year-old woman who developed acute hepatitis after taking shou-wu-pian for eight months, suggesting that Chinese herbal preparations can sometimes cause liver damage.

This review summarizes current and emerging treatments for common hair loss conditions, highlighting good evidence for androgenetic alopecia but noting the lack of long-term data for alopecia areata and cicatricial alopecias.

This review discusses hormone-modulating therapies for androgen-mediated cutaneous disorders in women but reports no new clinical results and highlights the need for more rigorous studies.

This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.